The effect of 16E5 on actin filaments may be unique to the C127 rodent fibroblasts used in their study, since we previously have shown that 16E5 does not perturb actin filaments in human ectocervical cells (54), and the present study demonstrates that even a high level of 16E5 expression in COS cells does not alter the organization of actin, tubulin, vimentin, or cytokeratin filaments

The effect of 16E5 on actin filaments may be unique to the C127 rodent fibroblasts used in their study, since we previously have shown that 16E5 does not perturb actin filaments in human ectocervical cells (54), and the present study demonstrates that even a high level of 16E5 expression in COS cells does not alter the organization of actin, tubulin, vimentin, or cytokeratin filaments. In epithelial cells, 16E5 localizes to membranes of the ER and nuclear envelope with its C terminus exposed to the cytoplasm (32). confirmed that E5 prevented endosome maturation (acidification and enlargement) by inhibiting endosome fusion. The E5-dependent defect in vesicle fusion was not due to detectable disruption of actin, tubulin, vimentin, or cytokeratin filaments, suggesting that membrane fusion was being directly affected rather than vesicle transport. Perhaps most importantly, Oteseconazole while bafilomycin A1(like E5) binds to 16K and inhibits endosome acidification, it did not mimic the ability of E5 to inhibit endosome enlargement or the trafficking of EGF. Thus, 16E5 alters EGF endocytic trafficking via a pH-independent inhibition of vesicle fusion. High-risk human papillomaviruses (HPVs) are the causative agent of cervical cancer (63) and HPV type 16 (HPV-16) is associated with a majority of cervical malignancies worldwide (13). HPV-16 encodes three oncoproteins: E5, E6, and E7. While the contributions of E6 and E7 to cellular immortalization and transformation have been characterized in detail (20), the role of HPV-16 E5 (16E5) is poorly understood (53). Nevertheless, a number of studies suggest that 16E5 does contribute to the development of cervical cancer. Most high-risk HPV types encode an E5 protein (48), and targeted expression of the three HPV-16 oncogenes in basal epithelial cells of transgenic mice (4) leads to a higher incidence of cervical cancer than does the expression of E6 and E7 alone (44). In addition, targeted epithelial expression of 16E5 (without E6 and E7) in transgenic mice induces skin tumors (21). It may be noteworthy that unlike high-risk HPV-18, which integrates into the host DNA and potentially disrupts E5 gene expression (20,64), the HPV-16 genome often persists in episomal form in malignant lesions (12,16,24,36,42). Biological activities of 16E5 that may facilitate carcinogenesis include evading host immune detection by interfering with the transport of antigen-presenting major histocompatibility complex (MHC) class I molecules to the cell surface (6), promoting anchorage-independent Oteseconazole growth (33,41,52) and disrupting gap junctions responsible for cell-cell communication (37,58). Oteseconazole The 16E5 phenotype most frequently linked to the development of cancer is enhanced ligand-dependent activation of the epidermal growth factor receptor (EGFR) (15,41,46,52). 16E5 stimulates EGF-dependent cell proliferationin vitro(7,33,40,41,52,60) andin vivo(21), which might expand the population of basal or stemlike keratinocytes and thereby increase the probability that some of these cells would undergo malignant transformation. A number of studies indicate that 16E5 may enhance ligand-dependent EGFR activation by interfering with the acidification of early endosomes containing EGF bound to activated EGFRs (17,51,57). It has been hypothesized that 16E5 inhibits the H+V-ATPase Rabbit Polyclonal to MAST1 responsible for maintaining an acidic luminal pH in late endosomes and Oteseconazole lysosomes (28) by associating with the V-ATPase 16-kDa c subunit (16K) (1,5,14,22,46) and disrupting assembly of the V-ATPase integral (Vo) and peripheral (Vi) subcomplexes (10). In contrast, Thomsen et al. (57) reported that 16E5 inhibits early endosome trafficking in fibroblasts by completely depolymerizing actin microfilaments. Due to the unavailability of antibodies that recognize native 16E5 and 16K, direct association of 16E5 with 16K has only been observed by overexpressing epitope-tagged forms of both proteinsin vitro(5,46) orin vivo(1,14,22). It is uncertain, therefore, whether these associations occur when the proteins are expressed at physiological levels. In yeast, both wild-type 16E5 (10) and several 16E5 mutants that associate with 16K in COS cells (1) inhibit vacuolar acidification, although another study in yeast concludes the opposite (5). 16K is a component of the V-ATPase Vosubcomplex, which is assembled in the endoplasmic reticulum (ER) (28), and 16E5 localizes to the ER and nuclear envelope in epithelial cells (32,54). Thus, the export of Vofrom the ER could potentially be inhibited by a significant level of 16K binding to 16E5, although the differential alkalinization of endosomes rather than the Golgi apparatus (17) would require specificity for those proton pumps directed to those sites. In the present study, we generated an antibody against native 16K and used it to determine whether 16K/16E5 complexes formed in primary keratinocytes. We also synthesized a new pH-sensitive fluorescent EGF conjugate to evaluate whether there was a correlation between E5-induced EGFR activation, trafficking and endosome alkalinization. Finally, we simultaneously monitored EGFR endocytic trafficking (using pH-insensitive fluorescent.